Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой?


DOI: https://dx.doi.org/10.18565/pharmateca.2019.5.47-60

А.И. Синопальников

Российская медицинская академия непрерывного профессионального образования, Москва, Россия

В статье представлены клинические рекомендации по применению оптимальной эмпирической антибактериальной терапии больных инфекциями нижних дыхательных путей (ИНДП), основанные на соответствующей доказательной базе и адаптированные к тому или иному региону с учетом знания структуры локальной антибиотикорезистентности ключевых пневмотропных возбудителей. В этом контексте главной задачей рекомендаций наряду с очерчиванием ключевых диагностических и дифференциально-диагностических признаков ИНДП становится и внедрение в повседневную клиническую практику рационального применения антибиотиков, а именно отказ от их назначения при вирусных/предположительно вирусных инфекций дыхательных путей и удержание от использования менее эффективных из них там, где антибактериальная терапия показана.


Для цитирования: Синопальников А.И. Антибиотики и внебольничные инфекции нижних дыхательных путей. Кому? Какой? Фарматека. 2019;26(5):47–60. DOI: https://dx.doi.org/10.18565/pharmateca.2019.5.47-60 


Литература


1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095–128. Doi: 10.1016/S0140-6736(12)61728-0.

2. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;80:2224–60. Doi: 10.1016/S0140-6736(12)61766-8.

3. Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2197–2223. Doi: 10.1016/S0140-6736(12)61689-4.

4. Fleming-Dutra K.E., Hersh A.L., Shapiro D.J., et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA. 2016;315:1864–73. Doi: 10.1001/jama.2016.4151.

5. Bartlett J.G. Management of respiratory tract infections. 2nd ed. Lippincott Williams & Wilkins. Philadelphia, 1999.

6. Kraus E.M., Pelzl S., Szecsenyi J., Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) – guideline adherence in the German primary care setting: An analysis of routine data. PLoS One. 2017;12(3):e0174584. Doi: 10.1371/journal.pone.0174584.

7. McCullogh A.R., Pollack A.L., Hansen M.P., et al. Antibiotics for acute infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust. 2017;207:65–9.

8. Harbarth S., Balkhy H.H., Goossens H., et al. Antimicrobial resistance: one world, one fight! Antimicrob Resist Infect Control. 2015;4:49. Doi: 10.1016/j.jgar.2016.10.013.

9. Zumla A., Memish Z.A., Maeurer M., et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet. Infect. Dis. 2014;14:1136–49. Doi: 10.1016/S1473-3099(14)70828-X.

10. Appelbaum P.C. 2012 and beyond: potential for start of a second pre-antibiotic era? J Antimicrob Chemother. 2012;67:2062–68. Doi: 10.1093/jac/dks213.

11. Gould I.M., Bal A.M. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4:185–91. Doi: 10.4161/viru.22507.

12. Ball P., Baquero F., Cars O., et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31–40.

13. Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient department, and emergency departments, United States, 1997. Vital and Health Statistics, Series 13. Hyattsville, MD: National Center for Health Statistics; 1999. DHHS publications no. (PHS). 2000. 1714 p.

14. Llor C. Acute bronchitis: aetiology and treatment. Eur. Respir. Monogr. 2013;60:1–17.

15. Macfarlane J., Holmes W., Gard P., et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56:109–14.

16. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138–80.

17. Benninger M., Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J Fam Prac. 2008;57(2):5–11.

18. Breath sounds. From basic science to clinical practice. Eds. Priftis K.N., Hadjileontiadis L.J., Evard M.L. Springer International Publishing AG; Cham, Switzeland. 2018.

19. Синопальников А.И., Козлов Р.С. Внебо­льничные инфекции дыхательных путей. Руководство для врачей. М., 2007. 352 с.

20. Claessens Y.E., Debray M.P., Tubach F., et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192:974–82. Doi: 10.1164/rccm.201501-0017OC.

21. Aqassandjan M., Shurin G.V., Ma Y., Shurin M.R.C-reactive protein and lung diseases. Int J Biochem. Cell Biol. 2014;53:77–88.

22. Brink A.J., Van Wyk J., Moodley V.M., et al. The role of appropriate diagnostic testing in acute tract infections: an antibiotic stewardship strategy to minimize diagnostic uncertainty in primary care. S Afr Med J. 2016;106:30–7.

23. Wark P. Bronchitis (acute). BMJ. Clin Evid. 2015;7:1508–36.

24. Ott S.R., Rohde G., Lepper P.M., et al. The impact of viruses in lower respiratory tract infections of the adult. Part II: acute bronchitis, acute exacerbated COPD, pneumonia, and influenza. Pneumologie. 2010;64:18–27. Doi: 10.1055/s-0029-1215197.

25. Martinez F.J. Acute bronchitis: state of the art diagnosis and therapy. Compr Ther. 2004;30:55–69.

26. Liapikou A., Torres A. The clinical management of lower respiratory tract infections. Exp Rev Respir Med. 2016;10:441–52.

27. Rohani P, Drake J.M. The decline and resurgence of pertussis in the US. Epidemics. 2011;3:183–88. Doi: 10.1016/j.epidem.2011.10.001.

28. Masseria C., Krishnarajah G. The estimated incidence of pertussis in people aged 50 years old in the United States, 2006–2010. BMC. Infect. Dis. 2015;15:534. Doi: 10.1186/s12879-015-1269-1.

29. Gerber J.S. Improving Outpatient Antibiotic Prescribing: Another Nudge in the Right Direction. JAMA. 2016;315:558–59. Doi: 10.1001/jama.2016.0430.

30. Evertsen J., Baumgardner D.J., Regnery A., et al. Diagnosis and management of pneumonia and bronchitis in outpatient primary care practices. Prim Care Respir J 2010;19:237–41. Doi: 10.4104/pcrj.2010.00024.

31. Harris A.M., Hicks L.A., Qaseem A., et al. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425–34. Doi: 10.7326/M15-1840.

32. Smith S.M., Fahney T., Smucny J., Becker L.A. Antibiotic for acute bronchitis (Review). Cochrane Database Syst Rev. 2017;6:CD 000245. Doi: 10.1002/14651858.CD000245.pub4.

33. Harris A.M., Hicks L.A., Qaseem A., et al. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425–34. Doi: 10.7326/M15-1840.

34. Tan T., Little P., Stokes T. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ. 2008;337:a437. Doi: 10.1136/bmj.a437.

35. www.nice.org.uk/CG069 (accessed 28 October 2015).

36. Козлов Р.С., Зырянов С.К., Синопальников А.И., Рязанцев С.В. Эмпирическая антибактериальная терапия инфекций дыхательных путей с учетом факторов риска резистентной флоры. Резолюция совета экспертов. Справочник поликлинического врача. 2018;1:6–10.

37. Altunaiji S., Kukuruzovic R., Curtis N., Massie J.Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2007;3:CD004404.

38. Macfarlane J. Lower respiratory tract infection and pneumonia in the community. Sem Respir Infect. 1999;14:151–62.

39. Hoyert D.L., Xu J. Death: preliminary data for 2011. Natl Vital Stat Rep. 2012;61:1–51.

40. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759–76.

41. Ewig S., Birkner N., Strauss R., et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64:1062–69. Doi: 10.1136/thx.2008.109785.

42. Cilloniz C., Rodriguez-Hurtado D., Torres A. Characteristics, and management of community-acquired pneumonia in the era of global aging. Med Sci. 2018;6:35–52. Doi: 10.3390/medsci6020035.

43. Cilloniz C., Ardanuy C., Vila J., Torres A. What is the clinical relevance of drug-resistant pneumococcus? Curr Opin Pulm Med. 2016;22:227–34. Doi: 10.1097/MCP.0000000000000262.

44. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9. Doi: 10.1136/thx.2009.129502.

45. Herrero S.F., Olivas B. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med. 2012;33:220–31.

46. Musher D.M., Abers M.S., Bartlett J.G. Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus. Clin Infect Dis. 2017;65:1736–44. Doi: 10.1093/cid/cix549.

47. Marchello C., Dale A.P., Thai T.N., et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: av meta-analysis. Ann Fam Med. 2016;14:552–66.

48. Cilloniz C., Torres A., Niederman M., et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med. 2016;42:1374–86. Doi: 10.1007/s00134-016-4394-4.

49. Внебольничная пневмония. Клинические рекомендации (проект), 2018. www.antibiotic.ru.

50. Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999;159:256272.

51. Meehan T.P., Fine M.J., Krumholz H.M., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278:2080–84.

52. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164:637–44.

53. Bjerre L.M., Verheij T.J., Kochen M.M. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2009;4:CD002109. Doi: 10.1002/14651858.CD002109.pub3.

54. Torumkuney D., Mayanskiy N., Edelstein M., et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Russia. J Antimicrob Chemother. 2018;73(5):14–21. Doi: 10.1093/jac/dky065.

55. Cherazard R., Epstein M., Doan T.L., et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther. 2017;24:361–69. Doi: 10.1097/MJT.0000000000000551.

56. Wiersinga W.J., Bonten M.J., Boersma W.G., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth Med J. 2018;76:4–13.

57. Boyles T.H., Brink A., Calligaro G.L., et al. South Africa guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9:1469–502. Doi: 10.21037/jtd.2017.05.31.

58. Garin N., Genne D., Carballo S., et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA. Intern. Med. 2014;174:1894–901. Doi: 10.1001/jamainternmed.2014.4887.

59. Ranzani O.T., Taniguchi L.U., Torres A. Severity scoring systems for pneumonia: current understanding and next steps. Curr Opin Pulm Med. 2018;24:227–36. Doi: 10.1097/MCP.0000000000000468.

60. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.

61. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.

62. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect. Dis. 2007;44(2):27–72.

63. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–84. Doi: 10.1086/589754.

64. Espana P.P., Capelastegui A., Gorordo I., et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174:1249–56.

65. Singer M., Deutschman C.S., Seymour C.W., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10. Doi: 10.1001/jama.2016.0287.

66. Zhang Y.Q., Zou S.L., Zhao H., et al. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. Am J Emerg Med. 2018;36(10):1759–65. Doi: 10.1016/j:ajem.2018.01.079.

67. Raz-Pasteur A., Shasha D., Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents. 2015;46:242–48. Doi: 10.1016/j.ijantimicag.2015.04.010.

68. Ruhe J., Mildvan D. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward? Infect Dis Clin North Am. 2013;27:115–32. Doi: 10.1016/j.idc.2012.11.004.

69. Postma D.F., van Werkhoven C.H., van Elden L.J., et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372:1312–23. Doi: 10.1056/NEJMoa1406330.

70. Hajj E.L., Turgeon R.D., Wilby K.J. Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review. Int J Clin Pharm. 2017;39:26–32. Doi: 10.1007/s11096-016-0417-z.

71. Ortiz-Ruiz G., Vetter N., Isaacs R., et al. Ertapenem versus for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double-blind studies. J Antimicrob Chemother. 2004;53(2):ii59–66.

72. Murcia J.M., Gonzales-Comeche J., Marin A.,et al. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clin Microbiol Infect. 2009;15:1046–50. Doi: 10.1111/j.1469-0691.2009.02843.x.

73. Lisboa T., Salluh J.L., Friedman G. Macrolides and respiratory infection in critically ill patients: what is the next step? Minerva Anestesiol. 2016;82:221–29.

74. Horita N., Otsuka T., Haranaga S., et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirol. 2016;21:1193–2000. Doi: 10.1111/resp.12835.

75. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых, 2014 (www.pulmonology.ru).

76. Global initiative for Chronic Obstructive Lung Disease. GOLD Report 2018 (www.copdgold.com).

77. Seemungal T.A., Donaldson G.C., Bhowmik A.,et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–13.

78. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with COPD. Thorax. 2005;60:925–31.

79. Almagro P., Calbo E., Ochoahe Echaguen A., et al. Mortality after hospitalized for COPD. Chest. 2002;121:1441–48.

80. Bafadhel M., McKenna S., Terry S., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–71. Doi: 10.1164/rccm.201104-0597OC.

81. George S.N., Garcha D.S., Mackay A.J., et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44:87–96. Doi: 10.1183/09031936.00223113.

82. Siddiqi A., Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Intern J COPD. 2008;3:31–44.

83. Allegra L., Blasi F., Diano P., et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med. 2005;99:742–47.

84. Eller J., Ede A., Schaberg T., et al. Infective exacerbations of chronic bronchitis: relation between bacterial etiology and lung function. Chest. 1998;113:1542–48.

85. Lode H., Allewelt M., Balk S., et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection. 2007;35:143–49.

86. Monso E., Garcia-Aymerich J., Soler N., et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003;131:799–804.

87. Garcia-Vidal C., Almagro P., Romani V., et al. Pseudomonas aeruginosa in patients hospitalized for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072–78.

88. Miravitlles M., Espinosa C., Fernandez-Laso E., et al. Study Group of bacterial infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–6.

89. Gallego M., Pomares X., Espasa M., et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC. Pulm Med. 2014;14:103. Doi: 10.1186/1471-2466-14-103.

90. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.

91. Puhan M.A., Vollenweider D.J., Latshang T.,Steurer-Stey C.A. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007;8:30.

92. Vollenweider D.J., Jarrett H., Steurer-Stey C.A., et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;12:CD010257. Doi: 10.1002/14651858.CD010257.

93. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic pulmonary obstructive disease in adults in primary and secondary care (partial update). London, National Clinical Guideline Centre, 2004.

94. Wedzicha J.A., Miravitlles M., Hurst J.R., et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791. Doi: 10.1183/13993003.00791-2016.

95. Stockley R.A., O’Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638–45.

96. Miravitlles M., Kruesmann F., Haverstock D., et al. Sputum color and bacteria in chronic bronchitis exacerbations: A pooled analysis. Eur Respir J. 2012;39:1354–60. Doi: 10.1183/09031936.00042111.

97. Soler N., Agusti C., Angrill J., et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29–35.

98. Llor C., Moragas A., Hernandez S., et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD. Am J Respir Crit Care Med. 2012;186:716–23. Doi: 10.1164/rccm.201206-0996OC.

99. Celli B.R., MacNee W., ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004;23:932–46.

100. Feldman C., Richards G. Appropriate antibiotic management of bacterial lower respiratory tract infections. F1000 Research. 2018;7:1121. Doi: 10.12688/f1000research.14226.1.

101. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17(6):1–59. Doi: 10.1111/j.1469-0691.2011.03672.x.

102. Rothberg M.B., Pekow P.S., Lahti M., et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:2035–42. Doi: 10.1001/jama.2010.672.

103. Miravitlles M., Murio C., Guerrero T., et al. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:928–33.

104. Wilson R., Schentag J.J., Ball P., Mandell L., 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639–52.

105. Wilson R., Allegra L., Huchon G., et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953–64.

106. Ruiz-Gonzalez A., Gimenez A., Gomez-Arbones X.,et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology. 2007;12:117–21.

107. Miravitlles M., Anzueto A. Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1052–7. Doi: 10.1164/rccm.201302-0289PP.


Об авторах / Для корреспонденции


Автор для связи: А.И. Синопальников, Российская медицинская академия непрерывного профессионального образования, Москва, Россия; e-mail: aisyn@list.ru; ORCID: https://orcid.org/0000-0002-1990-2042; Адрес: 123995, Россия, Москва, Баррикадная ул., 2/1, стр. 1


Похожие статьи


Бионика Медиа